Cargando…

CCNE1 Is a Putative Therapeutic Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma

Background: Ovarian clear cell carcinoma (OCCC) is resistant to platinum chemotherapy and is characterized by poor prognosis. Today, the use of poly (ADP-ribose) polymerase (PARP) inhibitor, which is based on synthetic lethality strategy and characterized by cancer selectivity, is widely used for ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawahara, Naoki, Yamada, Yuki, Kobayashi, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198755/ https://www.ncbi.nlm.nih.gov/pubmed/34070839 http://dx.doi.org/10.3390/ijms22115869

Ejemplares similares

ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma
por: Sato, Emi, et al.
Publicado: (2018)

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
por: Berns, Katrien, et al.
Publicado: (2018)

GSK-3β mediates the effects of HNF-1β overexpression in ovarian clear cell carcinoma
por: Kawahara, Naoki, et al.
Publicado: (2020)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression
por: Choi, Jae Yoon, et al.
Publicado: (2017)

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma
por: Takahashi, Kazuaki, et al.
Publicado: (2021)

Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
por: Maeda, Daichi, et al.
Publicado: (2010)

SMARCA4 loss irrelevant for ARID1A mutated ovarian clear cell carcinoma: A case report
por: Wagner, Samantha Kay, et al.
Publicado: (2023)

CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas
por: NAKAYAMA, KENTARO, et al.
Publicado: (2015)

Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma
por: Yano, Mitsutake, et al.
Publicado: (2019)

The HNF-1β―USP28―Claspin pathway upregulates DNA damage-induced Chk1 activation in ovarian clear cell carcinoma
por: Ito, Fuminori, et al.
Publicado: (2018)

The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level
por: Goldman, Aaron R., et al.
Publicado: (2016)

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
por: Kang, Eun‐Young, et al.
Publicado: (2022)

EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers
por: Alldredge, Jill K., et al.
Publicado: (2017)

GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors
por: Clemente, Valentino, et al.
Publicado: (2022)

CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer
por: Gorski, Justin W., et al.
Publicado: (2020)

ARID1A gene mutation in ovarian and endometrial cancers (Review)
por: TAKEDA, TAKASHI, et al.
Publicado: (2016)

Validation of magnetic resonance relaxometry R2 value and cyst fluid iron level for diagnosis of ovarian endometrioma
por: Imanaka, Shogo, et al.
Publicado: (2021)

CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance
por: Sapoznik, Stav, et al.
Publicado: (2017)

Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma
por: Chan, Angela MY, et al.
Publicado: (2020)

Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
por: Lin, Yu-Chien, et al.
Publicado: (2020)

Antioxidants and Therapeutic Targets in Ovarian Clear Cell Carcinoma
por: Amano, Tsukuru, et al.
Publicado: (2021)

Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma
por: Jung, Un Suk, et al.
Publicado: (2020)

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
por: Gallo, David, et al.
Publicado: (2022)

Relevance of ARID1A Mutations in Endometrial Carcinomas
por: De Leo, Antonio, et al.
Publicado: (2022)

Therapeutic significance of ARID1A mutation in bladder cancer
por: Conde, Marina, et al.
Publicado: (2022)

Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma
por: Ge, Huijuan, et al.
Publicado: (2021)

CCNE1 amplification among metastatic sites in patients with gynecologic high-grade serous carcinoma
por: Margolis, Benjamin, et al.
Publicado: (2021)

The Endometriotic Neoplasm Algorithm for Risk Assessment (e-NARA) Index Sheds Light on the Discrimination of Endometriosis-Associated Ovarian Cancer from Ovarian Endometrioma
por: Kawahara, Naoki, et al.
Publicado: (2022)

Multiple bronchiolar adenomas with malignant transformation and CCNE1 mutation: a case report and literature review
por: Li, Xiaojun, et al.
Publicado: (2021)

CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models
por: Xu, Haineng, et al.
Publicado: (2021)

Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report
por: Zhao, Yingchao, et al.
Publicado: (2022)

Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer
por: Fukumoto, Takeshi, et al.
Publicado: (2018)

ARID1A-mutated ovarian cancers depend on HDAC6 activity
por: Bitler, Benjamin G., et al.
Publicado: (2017)

CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes
por: Petersen, Shariska, et al.
Publicado: (2020)

Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signaling
por: Chandler, Ronald L., et al.
Publicado: (2015)

Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin
por: Zhang, Chao, et al.
Publicado: (2019)

Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity
por: De, Pradip, et al.
Publicado: (2019)

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
por: Cheng, Xuan, et al.
Publicado: (2021)

ARID1A protein expression is retained in ovarian endometriosis with ARID1A loss-of-function mutations: implication for the two-hit hypothesis
por: Yachida, Nozomi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8o0jebqqvki6rr9328nivmanv6